AstraZeneca plc vs Nerdwallet Inc — how do they compare? AstraZeneca plc trades at $168.85 (market cap $253.13B), while Nerdwallet Inc trades at $9.45 (market cap $616.53M). The key difference: AstraZeneca plc is far larger — about 410.6× Nerdwallet Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| AZN | NRDS | |
|---|---|---|
Market Cap | $253.13B | $616.53M |
Sector | Health | Financials |
52-Week High | $209.48 | $15.93 |
52-Week Low | $137.44 | $7.58 |
Enterprise Value | $279.37B | $530.83M |
Dividend Yield | 1.92% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
NerdWallet (NRDS) trades at $9.49, up 0.21% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported revenue of $836.6M in 2025, with net income of $48.7M and a net margin of 5.82%, showing a clear turnaround from losses in prior years. Recent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected, underscore operational strength. Analyst consensus is bullish with a $12.75 price target, implying 34% upside.
The outlook is positive given valuation multiples like a P/E of 10.2 and EV/EBITDA of 3.87, which appear attractive relative to growth. Key risks include reliance on search-driven traffic and macroeconomic sensitivity. Continued execution on revenue diversification and cost control supports further upside, but investors should monitor competitive pressures and consumer spending trends.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →